Literature DB >> 28842820

HIV Infection Is Not a Contraindication to Laparoscopic Sleeve Gastrectomy for Morbid Obesity.

Nancy Panko1, Gerrit Dunford2, Rami Lutfi2.   

Abstract

BACKGROUND: The efficacy of antiretroviral therapy has made HIV a chronic condition. The prevalence of obesity in HIV positive patients has subsequently risen and is present in 6-34% of men and 21-30% of women (Keithley et al. J Assoc Nurses AIDS Care 20(4):260-74, 2009). Sleeve gastrectomy is a safe and effective procedure for weight loss in the general population, but having HIV may bring hesitation to performing bariatric surgery for some practitioners.
OBJECTIVES: The aim of this study is to evaluate the safety and efficacy of laparoscopic sleeve gastrectomy (LSG) in patients with HIV.
METHODS: A retrospective analysis of prospectively collected data of patients with HIV who underwent LSG at a community hospital by a single surgeon was performed. Nine patients with HIV underwent LSG. Primary outcomes include weight loss at 6 and 12 months and postoperative CD4 count and viral load. Secondary outcomes include alteration to antiretroviral therapy (ART).
RESULTS: Our patients had a mean BMI of 46 (range 35-66) and were all well controlled on ART preoperatively. Mean weight loss at 12 months was 40 kg (range 21-55), with mean excess body weight loss 69% (range 42-112). There were no significant changes in CD4 counts, and all patients continued to have undetectable viral loads at 1 year postoperatively. One patient had a change in ART, which was unrelated to bariatric surgery. There were no complications in our patient group.
CONCLUSION: This is the largest series to date evaluating sleeve gastrectomy in HIV-positive patients and further supports the safety and efficacy of sleeve gastrectomy in this patient population.

Entities:  

Keywords:  Antiretroviral therapy; HIV; Laparoscopic sleeve gastrectomy; Morbid obesity; Viral load

Mesh:

Substances:

Year:  2018        PMID: 28842820     DOI: 10.1007/s11695-017-2865-5

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  14 in total

1.  Bariatric surgery: An HIV-positive patient's successful journey.

Authors:  F Eddy; S Elvin; L Sanmani
Journal:  Int J STD AIDS       Date:  2015-02-06       Impact factor: 1.359

2.  Laparoscopic gastric bypass surgery in human immunodeficiency virus-infected patients.

Authors:  Rafael Fazylov; Eliana Soto; Stephen Merola
Journal:  Surg Obes Relat Dis       Date:  2007-10-23       Impact factor: 4.734

3.  Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.

Authors:  Michael A Horberg; Leo B Hurley; Daniel B Klein; Stephen E Follansbee; Charles Quesenberry; Jason A Flamm; Gary M Green; Tye Luu
Journal:  Arch Surg       Date:  2006-12

Review 4.  When patients cannot take pills: antiretroviral drug formulations for managing adult HIV infection.

Authors:  Chessa R Nyberg; Brooke Y Patterson; Meghan M Williams
Journal:  Top Antivir Med       Date:  2011 Aug-Sep

5.  Bariatric surgery outcomes in HIV-infected subjects: a case series.

Authors:  Henry Selke; Steven Norris; Danielle Osterholzer; Kenneth H Fife; Barbara DeRose; Samir K Gupta
Journal:  AIDS Patient Care STDS       Date:  2010-09       Impact factor: 5.078

6.  Factors influencing 30-day emergency visits and readmissions after sleeve gastrectomy: results from a community bariatric center.

Authors:  Thomas D Willson; Ameer Gomberawalla; Kimberley Mahoney; Rami E Lutfi
Journal:  Obes Surg       Date:  2015-06       Impact factor: 4.129

7.  Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

Authors:  Viviane D Lima; Richard Harrigan; Melanie Murray; David M Moore; Evan Wood; Robert S Hogg; Julio Sg Montaner
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

8.  Sleeve gastrectomy is a safe and efficient procedure in HIV patients with morbid obesity: a case series with results in weight loss, comorbidity evolution, CD4 count, and viral load.

Authors:  Marinos Fysekidis; Régis Cohen; Mohamed Bekheit; Joseph Chebib; Abdelghani Boussairi; Hélène Bihan; Marie Aude Khuong; Laurent Finkielsztejn; Gabriela Mendoza; Sophie Abgrall; Djiba Condé; Jean Marc Catheline
Journal:  Obes Surg       Date:  2015-02       Impact factor: 4.129

9.  Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions.

Authors:  Esther Cabrero; Laura Griffa; Angel Burgos
Journal:  AIDS Patient Care STDS       Date:  2010-01       Impact factor: 5.078

10.  Long-term virologic outcomes following bariatric surgery in patients with HIV.

Authors:  Steven Zivich; Margaret Cauterucci; Sara Allen; Marion Vetter; Christopher Vinnard
Journal:  Obes Res Clin Pract       Date:  2015-09-26       Impact factor: 2.288

View more
  4 in total

1.  Impact of bariatric surgery in patients with HIV infection: a nationwide inpatient sample analysis, 2004-2014.

Authors:  Prabin Sharma; Thomas R McCarty; Julius N Ngu; Michael O'Donnell; Basile Njei
Journal:  AIDS       Date:  2018-09-10       Impact factor: 4.177

2.  Sleeve Gastrectomy in Morbidly Obese HIV Patients: Focus on Anti-retroviral Treatment Absorption After Surgery.

Authors:  Chloé Amouyal; Marion Buyse; Lea Lucas-Martini; Déborah Hirt; Laurent Genser; Adriana Torcivia; Jean-Luc Bouillot; Jean-Michel Oppert; Judith Aron-Wisnewsky
Journal:  Obes Surg       Date:  2018-09       Impact factor: 4.129

Review 3.  Implications of Bariatric Surgery on the Pharmacokinetics of Antiretrovirals in People Living with HIV.

Authors:  Leena Zino; Jurjen S Kingma; Catia Marzolini; Olivier Richel; David M Burger; Angela Colbers
Journal:  Clin Pharmacokinet       Date:  2022-04-11       Impact factor: 5.577

4.  Antiretroviral Therapy Efficacy Post-Bariatric Weight Loss Surgery: A Case Series of Persons Living with Human Immunodeficiency Virus.

Authors:  Emily A Kaip; Nicole Y Nguyen; Jennifer M Cocohoba
Journal:  Obes Surg       Date:  2022-02-16       Impact factor: 3.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.